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httpcense.Abstract Background: The non thyroidal illness syndrome (NTIS) represents a risk factor for
prolonged mechanical ventilation in mechanically ventilated, critically ill patients admitted to the
ICU. It is unclear, whether the NTIS is only a biochemical prognostic marker or it actually contrib-
utes to the development and progression of respiratory failure.
Aim: To assess the thyroid function in patients with respiratory failure and to evaluate the
impact of thyroid dysfunction as well as thyroid hormone replacement therapy on patients’ out-
come.
Patients and methods: The study was conducted on 100 patients (51 females and 49 males), they
were divided into two groups, Group A (respiratory failure group), who were admitted to the Respi-
ratory ICU (RICU) and group B (non-respiratory failure group) who were admitted to the Inpa-
tient Chest Department of Zagazig University Hospitals Egypt. The respiratory failure group
(Group A) included sixty-four (64) patients with respiratory failure (according to ABG parameters)
30 males and 34 females. They included 30 patients with acute exacerbation of COPD, 5 patients
with acute severe bronchial asthma, 5 patients with severe pneumonia, 4 patients with acute pul-
monary embolism, 8 patients with ARDS and 12 patients with acute exacerbation of IPF. This
respiratory failure group included 43 patients who were on invasive mechanical ventilation and
21 respiratory failure patients who were non-mechanically ventilated. Group (B) included thirty-
six (36) patients without respiratory failure according to ABG parameters as a control group (19
males and 17 females). There were 11 patients with acute exacerbation of COPD, 10 patients with62248163.
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514 R.M. Nafae et al.exacerbated bronchial asthma, 6 patients with exacerbated IPF, 6 patients with pneumonia and 3
patients with acute pulmonary embolism. All patients were subjected to calculation of APACHE
P score, PaO2/FiO2 ratio and estimation of thyroid hormones (TSH, free T3 and free T4) at the
1st, 3rd and 10th day of admission. Those who were still having ESS at the 10th day (16 patients)
and were not improving clinically, were subdivided randomly into two subgroups. Each of them
comprised 8 patients. One group was given L-thyroxin replacement therapy (The replacement
group) beside conventional appropriate management. The other group (8 patients) was followed
by conventional appropriate management only without replacement therapy (The non-replacement
group). L-Thyroxine 100 lg daily is administered for 7 weeks. At the 7th week, a fourth set of thy-
roid hormone estimation was done for the patients of the replacement and non-replacement groups.
Patients’ outcome was assessed after 7 weeks of admission and labeled as the following: 1-death, 2-
successfully treated and discharged.
Results: Respiratory failure patients showed evidence of euthyroid sick syndrome (ESS) at the
1st, 3rd and 10th days of admission with a frequency of 31.2%, 79.6% and 43.7% respectively while
none of the control group showed evidence of (ESS) and the difference was statistically signiﬁcant.
There were highly signiﬁcant negative correlation between serum levels of free T3 and TSH and
each of the duration of mechanical ventilation and length of ICU stay. There was signiﬁcant neg-
ative correlation between APACHE P score and serum level of freeT3 in the respiratory failure
group. There was non signiﬁcant impact of thyroid hormone levels on patients’ outcome. There
was non signiﬁcant difference in the levels of thyroid hormones between replacement and non
replacement groups at the 7th week of the study.
Conclusion: A state of hypothyroidism or euthyroid sick syndrome (ESS) is commonly found
among patients with respiratory failure and this is related to the severity of the disease. ESS repre-
sents a risk factor for prolonged mechanical ventilation and length of ICU stay. L-thyroxin replace-
ment therapy has no signiﬁcant impact on patients’ outcome.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Open access under CC BY-NC-ND license.Introduction
The thyroid hormone regulates the metabolism of proteins, lip-
ids and carbohydrates, and controls the activity of membrane-
bound enzymes. This hormone can also regulate the transcrip-
tion of numerous genes encoding both myoﬁbrillar and cal-
cium-regulatory proteins in myoﬁbers. The thyroid hormone
enhances mitochondrial oxidation and, thus, augments meta-
bolic rate. This effect on metabolic rate is probably responsible
for the association between the thyroid hormone and respira-
tory drive [1].
The non-thyroidal illness syndrome, also known as the
low T3 syndrome or euthyroid sick syndrome, describes a
condition characterized by abnormal thyroid function tests
encountered in patients with acute or chronic systemic ill-
nesses. The laboratory parameters of this syndrome include
low serum levels of triiodothyronine (T3) and high levels of
reverse T3, with normal or low levels of thyroxine (T4) and
normal or low levels of thyroid-stimulating hormone (TSH).
This condition may affect 60% to 70% of critically ill pa-
tients. The changes in serum thyroid hormone levels in the
critically ill patient seem to result from alterations in the
peripheral metabolism of the thyroid hormones, in TSH reg-
ulation, in the binding of thyroid hormone to transport-pro-
tein and in receptor binding and intracellular uptake.
Medications also have a very important role in these altera-
tions. Hormonal changes can be seen within the ﬁrst hours
of critical illness and, interestingly; these changes correlate
with ﬁnal outcome. Data on the beneﬁcial effect of thyroid
hormone treatment, on the outcome in critically ill patients
are so far controversial [2].Aim of the work
To assess the thyroid function in patients with respiratory fail-
ure and to evaluate the impact of thyroid dysfunction as well
as thyroid hormone replacement therapy on patients’ outcome.
Patients and methods
This studywas carried out at the intensive care unit and the inpa-
tient section of Chest Department, Zagazig University Hospi-
tals, Egypt in the period from October 2011 to October 2012.
Patients
The study was conducted on 100 patients (51 females and 49
males). They were divided into two groups, Group A (respira-
tory failure group), who were admitted to the Respiratory
Intensive Care Unit (RICU) and Group B (non-respiratory
failure group) who were admitted to the Inpatient Department
of Chest Diseases.
 Group (A) or respiratory failure group
Sixty-four (64) patients with respiratory failure were in-
cluded (according to ABG parameters) 30 males and 34 fe-
males with a mean age of 59.5 ± 6.4 years. Respiratory
failure patients either due to acute or chronic respiratory dis-
eases were diagnosed according to ABG parameters when an
arterial PaO2 less than 60 mmHg with or without increase in
arterial PaCO2 by more than 50 mmHg [3]. They were
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ratory failure:
I. Thirty (30) patients with acute exacerbation of chronic
obstructive pulmonary disease, who were diagnosed according
to (GOLD) [4] on the basis of:
(1) Symptoms of acute exacerbation of COPD (GOLD) [4]
Acute exacerbation of COPD was deﬁned as the presence of
any one of the following three major symptoms: (1) increased
sputum volume, (2) increased sputum purulence, or (3) in-
creased dyspnea. In addition, patients may have one or more
symptoms of fever, Sore throat or nasal discharge within past
5 days, increased wheezing, increased cough, increased respira-
tory rate >20% above baseline and increased heart rate
>20% above baseline. Severity of an acute exacerbation of
COPD was deﬁned as severe when patients had all three symp-
toms, moderate when patients had any two out of three symp-
toms, and mild when patients had any one out of three
symptoms [4].
(2) Lung function tests
FEV1 < 1L indicate a severe exacerbation
(3) Arterial blood gases
PaO2 < 60 mmHg and/or SaO2 < 90% with PaCO2 > 50
mmHg on room air at rest indicate respiratory failure type II
and if pH 7.30–7.35 would indicate severe exacerbation. In
addition, if PaO2 < 50 mmHg, PaCO2 > 70 mmHg and PH
7.30 would point toward a life-threatening episode it needs
critical management.
II. Five (5) patients with acute severe bronchial asthma
who were diagnosed according to (GINA) [5]:
 Moderate exacerbation parameters: breathless on talking,
talk phrases, usually agitated, increased respiratory rate,
over use of accessory muscles and suprasternal retractions,
loud wheeze, pulse 100–120/min. PEF after initial broncho-
dilator percent of predicted or percent of personal best was
60–80%, PaO2 (on air) > 60 mmHg and/or PaCO2 < 45 -
mmHg and SaO2% 91–95% (on air).
 Severe exacerbation parameters: breathless at rest, talk
words, usually agitated, increased respiratory rate > 30/
min., over use of accessory muscles and suprasternal retrac-
tions, loud wheeze, pulse was > 120/min pulsus paradoxus
often present > 25 mmHg (adult), PEF after initial bron-
chodilator was (<100 L/min), PaO2 (on air) <60 mmHg
and/or PaCO2 > 45 mmHg and SaO2%< 90% (on air).
III. Five (5) Patients with severe pneumonia who were
diagnosed according to Fine et al. [6]
Features such as fever (>38 C), pleural pain, dyspnea, and
tachypnea and signs on physical examination of the chest like
diminished movement on affected side, dullness and bronchial
breathing or diminished vesicular breathing were observed.
CXR and/or CT show ﬁnding like consolidation and para-
pneumonic pleural effusion.
The patient of severe pneumonia comes usually with one or
more of these signs in the word of CURB 65 (confusion, ur-
ea > 7 mmol/L, RR> 30, systolic blood pressure <90 or dia-
stolic blood Pressure <60 and age >65).
IV. Four (4) patients with acute pulmonary embolism
Management of a case of pulmonary embolism is by clinical
probability according to the Wells Clinical Prediction Score [7].Variable points
DVT symptoms/signs 3.0
PE is likely or more likely than alternative diagnosis 3.0
Heart rate > 100 1.5
Immobilization/Surgery in the previous 4 weeks 1.5
Previous DVT or PE 1.5
Hemoptysis 1.0
Malignancy 1.0
Total score pretest probability
<2.0 Low
2.0–6.0 Moderate
>6.0 High
Dichotomized score
#4 PE unlikely
>4 PE likelyV. Eight (8) patients with ARDS who were diagnosed
according to Mortelliti et al. [8] on the basis of:
 Identiﬁable associated condition. (e.g. near drowning, elec-
tric shock and others).
 Acute onset.
 Bilateral inﬁltrates on chest radiography.
 Acute lung injury (ALI) is present if PaO2/FiO2 ratio
is 6 300.
 Acute respiratory distress syndrome is present if PaO2/FiO2
ratio 6 200.
VI. Twelve (12) patients with exacerbated IPF who were
diagnosed according to Eric et al. [9].
Criteria of acute exacerbation of IPF:
Patients with established IPF (already known by history of
progressive dyspnea, pulmonary function is restrictive and
HRCT is diagnostic) satisfy the criteria for an acute exacerbation
if they have: (a) acute worsening of dyspnea within the last
month, (b) deterioration frombaseline inmeasures of pulmonary
function or gas exchange, (c) new inﬁltrates on plain chest ﬁlm or
CT and (d) the absence of other identiﬁable causes for decline.
Patients of group (A) (the respiratory failure group)were sub-
classiﬁed according to the need for mechanical ventilation into:
1. Group A 1
This group included the patients who were on invasive
mechanical ventilation. They were 43 patients. (among those
patients were 21 patients with acute exacerbation of COPD,5
patients with exacerbated IPF, 5 patients with acute severe
bronchial asthma, 8 patients with ARDS, 2 patients with acute
pulmonary embolism and 2 patients with severe pneumonia).
2. Group A 2
This group included 21 respiratory failure patients who
were non-mechanically ventilated. There were 9 patients with
acute exacerbation of COPD who did not need mechanical
ventilation, 2 patients with pulmonary embolism, 7 patients
with exacerbated IPF and 3 patients with severe pneumonia.
 Group (B) (non-respiratory failure group):The control
group
Thirty-six (36) patients without respiratory failure accord-
ing to ABG parameters as a control group (19 males and 17
516 R.M. Nafae et al.females) were included. There were 11 patients with acute exac-
erbation of COPD, 10 patients with exacerbated bronchial
asthma (moderate exacerbation), 6 patients with exacerbated
IPF, 6 patients with pneumonia and 3 patients with pulmonary
embolism with a mean age of 59.5 ± 4.7 years. All were al-
ready diagnosed according to the previous data which were
mentioned in group A and were not in respiratory failure.Exclusion criteria
1. Patients were excluded from the study if they had concom-
itant diseases such as renal failure, hepatic failure (creati-
nineP 3.5 and bilirubinP 6) (Normally most (80–90%)
of T3 is produced by monodeiodination of 40% of circulat-
ing T4, a reaction catalyzed by 50-monodeiodinases in
organs such as the liver and kidney. The remaining (10–
20%) is directly secreted by the thyroid gland) (Foteini
et al.) [2]. Other patients to be excluded are those with can-
cer, cerebrovascular stroke, cardiogenic pulmonary edema,
acute myocardial infarction, diabetic ketoacidosis, starva-
tion, sepsis, acute pancreatitis, cardiopulmonary bypass,
bone marrow transplantation and cardiac arrest.
2. Patients receiving drugs which alter thyroid function as
high dose of vasopressors (They cause suppression of TSH).
3. Exclusion of any pituitary hypothalamic disease, use of
iodine contrast agents in the previous 8 weeks, transfusion
of plasma proteins within 48 h prior to thyroid hormone
assessment.
4. Exclusion of patients with known hypothyroidism or
hyperthyroidism.
Methods
 All patients were subjected to the following:
(1) Full history taking from patients or their relatives who
were asked for smoking history, the principal symptoms of
respiratory disease (onset and duration)
(2) Thorough clinical examination including general and lo-
cal chest examination.
(3) APACHE II score was calculated.
The APACHE II score (Acute Physiology and Chronic
Health Evaluation) is a system for classifying patients in the
intensive care unit. Patients were evaluated by physiologic
scores and evaluation of chronic health status. Physiologic
scores correlate with severity of illness. The clinical status of
the patients of respiratory failure in ICU was usually reﬂected
by this score (Knaus et al.) [10].
(4) PaO2/FiO2 ratio was calculated:
From the ABG the following are interpreted:
– A simpliﬁed approach, used in the deﬁnition of acute lung
injury and the acute respiratory distress syndrome, to calcu-
late the PaO2/FiO2 ratio. Acute lung injury (ALI) is present
if Pao2/Fio2 ratio is 6 300.
– Acute respiratory distress syndrome is present if Pao2/Fio2
ratio 6 200. [8]
(5) Routine laboratory investigations including:– Serum electrolytes, kidney function tests, liver functions
tests and complete blood picture.
– D dimer whenever pulmonary embolism was suspected. It
was done for 10 cases.
(6) Electrocardiogram: Identify arrhythmias, ischemia and
ventricular hypertrophy.
(7) Plain chest X-ray: Previous chest X-rays were ﬁrst re-
viewed for assessing abnormality related to the disease and
new one is performed for conﬁrmation and to assess any dis-
eases like pneumonia, pleural effusion, lung ﬁbrosis, pneumo-
thorax etc.
(8) Echocardiography was done for patients with suspected
corpulmonale, or pulmonary hypertension accompanied with
acute pulmonary embolism.
(9) High resolution CT was revised and asked for those who
have IPF (13 patients) and who were non mechanically
ventilated.
(10) Magnetic Resonance pulmonary angiography (MRA):
was revised for patients who were suspected of having pulmon-
ary embolism and were non mechanically ventilated (5
patients).
(11) At the day of admission (1st day). Baseline serum TSH,
free T3 and free T4 were estimated.
(12) At the third day of admission (3rd day). Serum TSH,
free T3 and free T4 were re-estimated to detect any change
in their levels.
(13) At 10th day another set of thyroid function was done
excluding those who died.
(14) Those who still have ESS at 10th day (16 patients) and
not improving clinically were subdivided randomly into two
subgroups. Each of them comprised 8 patients. One group
was given replacement therapy (L-thyroxin replacement)
(replacement group) beside conventional appropriate manage-
ment. The other group (8patients) was followed by conven-
tional appropriate management only without replacement
therapy (non-replacement group). L-thyroxine 100 lg daily is
administered for 7 weeks according to Roberts and Ladenson
[11].
(15) At 7th week, a fourth set of thyroid function was done
for the patients of the replacement and non-replacement
groups.
(16) Patients’ outcome was assessed after 7 weeks of admis-
sion and labeled as the following: 1-death, 2-successfully trea-
ted and discharged.
Collection of samples and technique used for estimation of
thyroid hormone levels: [12]
Device used: COBAS E 411
Free T3: Principle of the procedure: competitive analog-
based immunoassay
Specimen collection and preparation: Serum samples can be
prepared according to common procedures used routinely in
clinical laboratory practice. Samples can be stored for 2 days
at 2–8 C or for 2 months at 20 C. The use of ultracentrifuge
is recommended to clear lipemic samples.
Volume required: 15 lL serum.
Reference value: 2.0–4.4 pg/ml
Free T4: Principle of the procedure: competitive analog-
based immunoassay.
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prepared according to common procedures used routinely in
clinical laboratory practice. Samples can be stored for 2 days
at 2–8 C or for 2 months at 20 C. The use of ultracentrifuge
is recommended to clear lipemic samples.
Volume required: 15 lL serum.
Reference value: 0.93–1.7 ng/dL.
TSH: Principle of the procedure: solid-phase immunomet-
ric assay.
Specimen collection and preparation: Serum samples can be
prepared according to common procedures used routinely in
clinical laboratory practice. Samples can be stored for 5 days
at 2–8 C or for 1 month at 20 C. The use of ultracentrifuge
is recommended to clear lipemic samples.
Volume required: 50 lL serum.
Reference value: 0.27–4.2 lIU/mL.
(17) Statistical analysis:
Data were entered, checked and analyzed using the Epi-
Info version 6 and SPSS for Windows version 8.
Data were summarized using:
1. The arithmetic mean ðXÞ: as an average describing the
central tendency of observations:
2. The standard deviation (SD): as a measure of dispersion
of the results around the mean:
3. Analysis of variance (ANOVA of F test): for comparison
of means of more than two groups.
4. Correlation study:
Correlation between variables was done using the correla-
tion coefﬁcient ‘‘r’’ this test detects if the change in one vari-
able was accompanied by a corresponding change in the
other variable or not.
5. Chi squared (X)2:
Used to ﬁnd the association between row and column
variables.
Level of signiﬁcance
For all above mentioned statistical tests done, the threshold of
signiﬁcance is ﬁxed at 5% level (P-value).Table 1 Percentage distribution of the studied patients (group A a
Thyroid status Group
Group A N= 64 G
No % N
Normal 44 68.7 3
ESS 20 31.2
TOTAL 64 100 3
Table 2 Percentage distribution of the studied patients (group AB)
Thyroid status Group
Group A N= 64 G
No % N
Normal 13 20.3 3
ESS 51 79.6
Total 64 100 3Results
Table 1 shows that 31.2% of patients with respiratory failure
(Group A) have ESS at the 1st day, while none of the control
group (Group B) has ESS and the difference was statistically
highly signiﬁcant.
Table 2 shows that 79.6% of patients with respiratory fail-
ure (Group A) show ESS at the 3rd day, while none of the con-
trol group (Group B) show ESS and the difference was
statistically highly signiﬁcant.
Table 3 shows that the level of TSH and FT3 was lower on
the third day than the ﬁrst day and the difference was statisti-
cally highly signiﬁcant while there is no signiﬁcant difference
regarding FT4 between 1st and 3rd day among respiratory fail-
ure patients.
Table 4 shows that there is no signiﬁcant difference regard-
ing FT3, FT4, and TSH between 1st and 3rd day among non
respiratory failure patients.
Table 5 and Fig. 1 show that there is a statistically highly
signiﬁcant difference in the number of normal and ESS pa-
tients at 1st, 3rd and10th days. The number of ESS patients
was more at 3rd day (79.6%) and least at 1st day (31.2%)
i.e. the 3rd day was the worst.
Table 6 shows that there is a signiﬁcant negative correlation
between each of FT3 and TSH and duration of MV at 3rd day
of the study, while no signiﬁcant correlation between FT4 and
duration of MV.
Table 7 shows that there is a statistically highly signiﬁcant
negative correlation between mean levels of FT3, FT4 and
TSH and length of stay in ICU at 3rd day in the respiratory
failure group.
Table 8 shows that there is a statistically signiﬁcant negative
correlation between FT3 and APACHE II score in the respira-
tory failure group at 1st day of ICU admission.
Table 9 shows that there is no signiﬁcant impact of thyroid
status on patients’ outcome at the third day of ICU admission
in the studied respiratory failure patients.
Table 10 and Fig. 2 show that there is no signiﬁcant differ-
ence in the thyroid hormone levels at 7thweek between replace-
ment and non-replacement groups.nd B) regarding their thyroid status at the 1st day of admission.
X P
roup B N= 36
o %
6 100 12.3 <0.001
0 0
6 100
at the 3rd day of admission.
X2 P
roup B N= 36
o %
6 100 55.2 <0.001
0 0
6 100
Table 3 Comparison between thyroid hormone levels at the
1st and 3rd day among patients of Group A.
Day Thyroid hormones
FT3 FT4 TSH
1st Day (Mean ± SD) 2.3 ± 0.7 1.1 ± 0.2 1.5 ± 0.9
3rd Day (Mean ± SD) 1.6 ± 0.6 1.15 ± 0.6 1.4 ± 0.9
T 5.4 1.7 4.5
P <0.001 >0.05 <0.001
Table 4 Comparison between thyroid hormone levels at the
1st and 3rd day among patients of Group B.
Day Thyroid function
FT3 FT4 TSH
1st Day (Mean ± SD) 2.6 ± 0.4 1.2 ± 0.2 2.2 ± 0.9
3rd Day (Mean ± SD) 2.8 ± 0.5 1.2 ± 0.2 2.3 ± 0.8
T 1.2 1.7 0.4
P >0.05 >0.05 >0.05
Thyroid  status 
0
20
40
60
80
100
10th day 3rd day 1st day
Normal ESS
Figure 1 Percentage distribution of group A patients regarding
their thyroid status at (1st, 3rd and 10th day) of the study.
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has no signiﬁcant impact on thyroid status.
Discussion
The prevalence of NTIS is about 11–18% in records of non-se-
lected hospitalized patients and increases up to 60–70% among
patients admitted to intensive care units. Considerable contro-
versy still exists on whether NTIS represents a physiologic
adaptive response to systemic illness, by which it lowers tissue
energy requirements or conversely a maladaptive state, which
induces a damaging hypothyroid state at the tissue level [13].
Severe hypothyroidism has several metabolic effects that
may adversely affect attempts at weaning. Although these in-
clude direct impairment of the diaphragm function and actual
myxoedema of these and other muscles, probably the domi-
nant effect is the blunting of ventilatory responses to hypoxia
and hypercapnia. Thyroid hormone replacement results in sig-
niﬁcant improvement in these ventilatory control parameters
[14].
In the differential diagnosis of low serum T3and T4 in the
critically ill patient, intensivists should include hypothyroid-
ism. Measurements of rT3 had been considered useful in differ-
entiating non thyroidal illness (high rT3) from secondary
hypothyroidism (low TSH), which should be associated with
low rT3. Subsequent studies however showed that rT3 does
not accurately distinguish the two states [13].Table 5 Percentage distribution of group A patients regarding thei
Thyroid status Day
1st day 3rd day
No % No %
Normal 44 68.7 13 2
ESS 20 31.2 51 7To date, there are few data on thyroid function in patients
with respiratory diseases due to pulmonary disorders, and
there are no data available on thyroid function in respiratory
failure patients needing invasive or noninvasive mechanical
ventilation [15].
So the aim of this work was to study the thyroid function
among patients with respiratory failure due to various etiolo-
gies to check the frequency of ESS and its effect on the prog-
nosis of the original disease.
In this study, two groups of patients were studied: Group
(A) (respiratory failure group); comprised 64 patients with
respiratory failure, there were 30 males and 34 females (with
a mean age of 59.5 ± 6.4 years) and they were chosen from
ICU of the chest department. Another group (B) (control
group or non respiratory failure patients) comprised 36 pa-
tients (with a mean age of 59.5 ± 4.7 years, 19 males and 17
females). They were chosen from general ward of the Chest
Department of Zagazig University Hospitals. They were
matched with the respiratory failure group regarding age and
sex. They were having the same chest diseases (apart from
ARDS subgroup) of group (A) but without respiratory failure.
In this work and on the initial presentation (1st day) 20 pa-
tients (31.2%) of group A (respiratory failure group) were hav-
ing ESS and (68.7%) did not have ESS while none in group B
(non-respiratory failure group) were having this defect. This
means that the deranged blood gases and severity of the dis-
ease were mostly the main factor causing ESS. On the third
day of admission to the ICU the repeated values of thyroid
hormones showed that the number of ESS patients increased
from 20 patients (31.2%) to 51 patients (79.6%) (Tables 1
and 2).
In agreement with our study, De Groot, (2006) [16] found
in a cohort study of consecutive acutely ill, hospitalized older
patients, the prevalence of NTIS was 31.9%. Also Datta and
Scalise [14] found near similar results.
Bacakoglu et al. [17] found that, higher rates of thyroid
function test (TFT) abnormalities (in at least one of the thy-
roid hormone levels mostly FT3) in what is so called ESSr thyroid status at (1st, 3rd and 10th day) of the study.
X2 P
10th day
No %
0.3 32 50 31.3 <0.001
9.6 28 43.7
Table 6 Correlation between thyroid hormone levels and
duration of MV at 3rd day of study among patients of group
(A).
Thyroid hormones MV
r p
FT3 0.57 <0.001
FT4 0.24 >0.05
TSH 0.56 <0.001
Table 7 Correlation between thyroid hormone levels and
length of stay in ICU at 3rd day among patients of group (A).
Thyroid function ICU stay
r P
FT3 0.50 <0.001
FT4 0.35 <0.001
TSH 0.49 <0.001
Table 8 Correlation between FT3 at 1st day and APACHE P
score in group (A).
r P
APACHE and FT3 0.34 <0.01
Table 9 Thyroid status at the third day and outcome of
studied patients in group (A).
Thyroid status Outcome X2 P
Normal No. = 13 ESS No. = 51
No. % No. %
Death 0 0 9 17.6 2.4 >0.05
Discharged 13 100 42 82.4
Table 10 Comparison of thyroid hormone levels at 7th week
between replacement and non-replacement groups.
Replacement
group n= 8
Non-replacement
group = 8
t P
Mean ± SD Mean ± SD
FT3 1.1 ± 0.4 1.2 ± 0.5 0.2 >0.05
FT4 1.1 ± 0.12 1 ± 0.04 1.2 >0.05
TSH 0.7 ± 0.6 0.3 ± 0.2 0.6 >0.05
0
0.5
1
1.5
2
FT3 FT4 TSH
Replacement Non- replacement 
Figure 2 Comparison of thyroid hormone levels at 7th week
between replacement and non-replacement groups.
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compared to those with less severe disease and no respiratory
failure. Burman and Wartofsky [18], illustrated that several
mechanisms can contribute to the inhibition of 50-monodeio-
dination and therefore to the low serum T3 concentrations in
critically ill patients with non thyroidal illness: (A) Exogenous
glucocorticoid therapy. (B) Circulating inhibitors of deiodin-
ase activity, such as free (non-esteriﬁed) fatty acids. (C) Treat-
ment with drugs that inhibit 50-monodeiodinase activity, suchas amiodarone and high doses of propranolol. (D) Cytokines
(such as tumor necrosis factor, interferon-alpha, NF-kB and
interleukin-6) [18].
The results of this work showed that, there is statistically
highly signiﬁcant difference in the number of normal and ESS
patients at 1st, 3rd and 10th days. The number of ESS patients
was more at 3rd day (79.6%) and least at 1st day (31.2%) while
the number of normal patients was more at 1st day (68.7%) and
least at 3rd day (20.3%) (Table 5 and Fig. 1).
Also it was found that, in group A the mean levels of TSH
and FT3 were lower on the third day than the ﬁrst day and the
difference between the 1st and 3rd days was statistically highly
signiﬁcant (Tables 3)
In contrast, no signiﬁcant difference regarding FT3, FT4,
and TSH between 1st and 3rd day among patients of group
B was observed (Tables 4).
In agreement with our results, Plikat et al. [19] studied dif-
ferent medical diseases with acute illness and examined thyroid
laboratory values for TSH, FT3, and FT4 at days 1, 5 and 10.
They found that, 44.1%, 68.4% and 34% at day 1, 5 and 10
had low serum FT3 levels indicating a NTIS, either with nor-
mal or reduced serum TSH levels.
During the chronic phase of critical illness, serum TSH lev-
els are reduced and correlate with low serum T3 level. Normal-
ization or a frank elevation of serum TSH may herald recovery
from the critical illness [20].
Our explanation of this point is consistent with that of Me-
bis et al. [21] who stated that, in the acute phase of critical ill-
ness, the low serum T3 values are mainly attributed to changes
in the circulation of peripheral organs such as the liver and
kidney. These comprise of reduced thyroid hormone binding,
reduced uptake of thyroid hormone by the cells and increased
inactivation by the iodothyronine deiodinases.
The results of this study showed that there is signiﬁcant
negative correlation between FT3 and TSH at 3rd day of study
and duration of MV (Tables 6).
In accordance with the results of the current work, Datta
and Scalise [14] reported that, the patients with ESS were more
frequently treated with invasive mechanical ventilation when
compared to those with normal thyroid function results. Fur-
thermore, both the period of that invasive mechanical ventila-
tion and the in-hospital stay were higher.
Also, our ﬁndings are in agreement with those of Okutan
et al. [22] who assessed thyroid function in mechanically venti-
lated patients and found that FT3 level was the only factor sig-
niﬁcantly associated with an increased period of invasive
mechanical ventilation.
The results of this work showed that, there is a highly sig-
niﬁcant negative correlation between thyroid hormone levels at
3rd day of study and length of stay in ICU (Table 7)
Table 11 Percentage distribution of the patients of group A according to their thyroid status with special reference to the cause of
respiratory failure at 1st, 3rd, 10th day.
1st Day 3rd Day 10th Day
Normal ESS Normal ESS Normal ESS
No % No % No % No % No % No %
COPD 15 50 15 50 3 10 27 90 11 36.6 19 63.33
IPF 7 58.3 5 41.7 3 25 9 75 7 58.3 5 41.6
BA 5 100 0 0 1 20 4 80 3 60 2 40
ARDS 8 100 0 0 1 12.5 7 87.5 3 37.5 1 12.5
EMBOLISM 4 100 0 0 2 50 2 50 3 75 1 25
PNEUMONIA 5 100 0 0 3 60 2 40 5 100 0 0
X2 = 19.4 P=NS (P> 0.05).
520 R.M. Nafae et al.Near similar results were mentioned by Peeters et al. [23].
They studied patients with NTIS who had an increased length
of stay in ICU. The median duration for patients with low FT3
was 6 days compared with 3 days for normal thyroid patients.
Patients with low FT3 and FT4 stayed signiﬁcantly longer at
ICU.
In the current study there was signiﬁcant negative correla-
tion between FT3 at 3rd day and APACHE II score in the
studied respiratory failure patients (Table 8).
These results match with the study done by Scoscia et al. [15]
who stated that, there were negative signiﬁcant correlations be-
tween, FT3 and APACHE score (inverse correlation), FT3 and
the mortality rate, APACHE score and the mortality rate.
The results of our study showed that there is no signiﬁcant
relation between outcome and thyroid hormone levels at 3rd
day in the studied respiratory failure patients (Tables 9).
In support with the result of this work, Van den Berghe [24]
found that, in spite of the course of the disease (clinical condi-
tions and length of hospital stay) it was worse in patients with
reduced FT3 values but, plasma FT3 could not predict the
outcome.
Also, Plikat et al. [19] found that about 44% of patients
admitted in the medical intensive care unit of University Hos-
pital of Regensburg had ESS. There was no signiﬁcant corre-
lation between FT3 and the mortality rate.
In contrary with the results of the current study, Dietrich
et al. [25] reported that, during hospitalization (mean duration
10 ± 5 days), the overall cumulative death rate was 8.3%, sig-
niﬁcantly higher in patients with low T3 syndrome as com-
pared to those without. Indeed, serum FT3 levels were
signiﬁcantly lower in patients who died during hospitalization
with an inverse relationship between death rate and FT3 value.
Also, the ﬁndings of the present study are in contrary with
those of Iervasi et al. [26] who found that, the reduced FT3 lev-
els were the only signiﬁcant predictor of death in respiratory
failure patients and concluded a preliminary data that, the
FT3 plasma concentration may be used as a marker of disease
severity and outcome in patients with respiratory failure due to
pulmonary disorder.
The results of the current work showed that, there is no sig-
niﬁcant difference in the thyroid function tests between the
replacement and non-replacement group (at 7th week) (Ta-
ble 10). This may be explained according to DeRuiter [27]
who illustrated that when people are ill, malnourished, or have
had surgery, the T4 form of thyroid hormone is not convertednormally to the T3 form. Despite this abnormal conversion,
the thyroid gland continues to function and to control the
body’s metabolic rate normally. Because no problem exists
with the thyroid gland, no treatment is needed. Laboratory
tests show normal results once the underlying illness resolves.
Stathatos et al. [28] concluded that, in ICU patients, who
were clinically euthyroid but have the altered thyroid function
tests of the sick euthyroid syndrome, there is no proven beneﬁt
in replenishing them with T4 and certainly no improvement in
overall mortality.
Our study showed that the initial cause of respiratory fail-
ure has no signiﬁcant effect on thyroid status at all days of the
study (Tables 11). This means that the state of critical illness
itself is the leading cause of ESS whatever its etiology.
In agreement with our study Uzen et al. [29] noted that
there was no signiﬁcant difference in mean levels of TSH,
FT3 and FT4 between COPD and the control group. Serum
level of TSH was lower than normal limits in 20 of 62 patients
with COPD.
Conclusion
 A state of hypothyroidism (ESS) or euthyroid sick syn-
drome is commonly found among patients with respiratory
failure and this is related to the severity of the disease.
 ESS represents a risk factor for prolonged mechanical ven-
tilation and length of ICU stay.
 L-Thyroxin replacement therapy has no signiﬁcant impact
on patients’ outcome.Conﬂict of Interest
None declared.
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